UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2523, 2026

MiniMed Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-43183	33-3985981
(State or other jurisdiction of incorporation)	(Commission File Number)	(~~IRS~~I.R.S. Employer Identification No.)

18000 Devonshire St.

Northridge, CA 91325

(Address of principal executive offices) (Zip Code)

(763) 514-4000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.01 par value		MMED		The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 75.0102. ~~Regulation~~Departure FDof ~~Disclosure~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 18 23, 2026, the Compensation and Talent Committee (the “Committee”) of the Board of Directors of MiniMed Group, Inc. (the “~~MiniMed~~Company”) ~~announced that~~ approved the ~~U.S.~~MiniMed ~~Food~~Severance ~~and~~Pay ~~Drug~~Plan ~~Administration~~for Executives (the “~~FDA~~Severance Plan”) ~~has~~and ~~cleared~~applicable ~~the~~severance ~~MiniMed~~benefit ~~Flex™,~~practices and alevels ~~next-generation~~that ~~discreet,~~would ~~smartphone-controlled~~be ~~insulin~~applicable ~~pump.~~to ~~The~~the ~~clearance~~Company’s ofnamed executive officers and the MiniMed ~~Flex~~Group, byInc. Change of Control Severance Plan (the ~~FDA~~“COC ~~was~~Severance ~~several~~Plan”). ~~months~~Each ~~earlier than~~of ~~anticipated,~~the ~~and~~Company’s ~~will~~named ~~facilitate~~executive officers is a participant in the ~~earlier~~COC ~~commercialization~~Severance Plan ofand ~~this~~is ~~key~~eligible ~~MiniMed~~to ~~product~~participate in the Severance Plan.

~~The research and development of the~~ MiniMed ~~Flex was~~Severance ~~funded~~Pay inPlan ~~part by affiliates of Blackstone Life Sciences Advisors L.L.C. (“Blackstone”). Under the research and development agreement between MiniMed and Blackstone, in exchange~~ for ~~funding~~Executives the development of the MiniMed Flex, during the first two years following regulatory approval in the U.S. and commercial launch of the MiniMed Flex, Blackstone will earn the greater of: (i) mid-to-high single digit royalty percentage of applicable net sales, and (ii) a specified minimum payment of $157 million for this product. MiniMed is expected to recognize a one-time charge of $157 million in the fourth quarter of fiscal year 2026 related to the series of future payments due to Blackstone for this product.

~~Forward~~Certain executives of the Company at the Vice President level and above, including each named executive officer, are eligible to participate in the Severance Plan following an eligible termination of employment. Payment of any such benefits is subject to the participant’s execution and non-~~Looking~~revocation ~~Statements~~of ~~Disclaimer~~a release of claims, and satisfaction of applicable conditions.

~~This~~In ~~filing~~connection ~~contains~~with ~~forward-looking statements within~~ the ~~meaning~~adoption of the ~~Private~~Severance Plan, ~~Securities~~the ~~Litigation~~Committee ~~Reform~~also ~~Act~~approved ofcertain ~~1995,~~severance ~~which~~practices ~~are~~and ~~subject~~levels tothat ~~risks~~would ~~and~~be ~~uncertainties,~~applicable ~~including risks related~~ to ~~MiniMed~~the Company’s ~~anticipated~~named ~~financial~~executive officers ~~results~~under ~~for~~ the ~~fourth~~Severance ~~quarter~~Plan upon an eligible termination of ~~fiscal~~employment ~~year~~not ~~2026~~in ~~and~~connection ~~for~~with ~~fiscal~~a ~~year~~change ~~2027~~of control. ~~These~~Upon ~~risks~~such a termination, ~~and~~subject ~~uncertainties~~to ~~are~~the ~~described~~execution inand ~~MiniMed’s~~non-revocation ~~filings~~of ~~with~~a ~~the~~release ~~U.S.~~of ~~Securities~~claims and ~~Exchange~~satisfaction ~~Commission.~~of Inapplicable ~~some~~conditions ~~cases,~~under ~~you~~the ~~can~~Severance ~~identify~~Plan, ~~these~~each ~~statements~~named byexecutive ~~forward-looking~~officer ~~words~~would orbe ~~expressions,~~entitled ~~such~~to asreceive: ~~“anticipate,”~~(i) ~~“believe,”~~a ~~“could,”~~lump-sum ~~“estimate,” “expect,”~~cash ~~“forecast,”~~severance ~~“intend,”~~payment ~~“looking~~equal ~~ahead,”~~to ~~“may,”~~two ~~“plan,”~~times ~~“possible,” “potential,”~~the ~~“project,”~~sum ~~“should,”~~of ~~“going~~the ~~to,”~~named executive ~~“will,”~~officer’s annual base salary and ~~similar~~target ~~words~~annual orbonus ~~expressions, the~~and ~~negative~~(ii) ora ~~plural~~lump-sum ofcash ~~such~~payment ~~words~~equivalent orto ~~expressions~~the ~~and~~cost ~~other~~of ~~comparable~~24 ~~terminology.~~months of ~~Actual~~continued ~~results~~medical ~~may~~and ~~differ~~dental ~~materially~~coverage ~~from~~under ~~anticipated results~~COBRA. ~~MiniMed~~The ~~does~~named ~~not~~executive ~~undertake~~officer towould ~~update~~not ~~its~~be ~~forward-looking~~entitled ~~statements~~to any additional or ~~any~~continued vesting of equity awards under the ~~information~~Severance ~~contained~~Plan, except in ~~this~~the ~~filing,~~case ~~including to~~such ~~reflect~~named ~~future~~executive ~~events~~officer oris ~~circumstances~~retirement-eligible.

~~SIGNATURES~~MiniMed Group, Inc. Change of Control Severance Plan

~~Pursuant~~The COC Severance Plan provides that, for a three year period following a change of control, each named executive officer is entitled to continued employment on terms no less favorable than those in effect during the ~~requirements~~90-day period immediately preceding the change of control. If, during such three-year period, the named executive officer is terminated without cause or resigns for good reason, subject to an effective release of claims, the ~~Securities~~named ~~Exchange~~executive ~~Act~~officer is entitled to receive: (i) a pro-rated annual bonus for the year of ~~1934~~termination, based on the higher ~~registrant~~of ~~has~~(x) ~~duly~~the ~~caused~~named ~~this~~executive ~~report~~officer’s average annual bonus paid over the immediately preceding three years (excluding any bonus paid by Medtronic plc or under a Medtronic plc incentive plan) or (y) the named executive officer’s most recently paid annual bonus (the higher of (x) and (y), the “Highest Annual Bonus”), (ii) a lump-sum cash payment equal to three times the sum of the named executive officer’s annual base salary and Highest Annual Bonus, (iii) benefits under the Company’s tax qualified retirement plan and any excess or supplemental retirement plan calculated assuming that the named executive officer’s employment had continued for three additional years, and (iv) continued health care and life insurance benefits for three years at the same after-tax cost to the named executive officer as in effect prior to the date of termination. The COC Severance Plan also provides that if the severance payments and benefits under the plan would trigger an excise tax for the named executive officer under Section 4999 of the Internal Revenue Code of 1986, such named executive officer’s severance payments and benefits will be ~~signed~~either onreduced ~~its~~to ~~behalf~~a level byat which the ~~undersigned~~excise ~~hereunto~~tax is not triggered or paid in full (which would then be subject to the excise tax), whichever results in the ~~duly~~better ~~authorized~~net after-tax position for such named executive officer.

	MiniMed Group, Inc.
Date: March 25, 2026	By:	/s/ Chad Spooner
	Name:	Chad Spooner
	Title:	Executive Vice President & Chief Financial Officer

The descriptions of the Severance Plan and the COC Severance Plan set forth under this Item 5.02 do not purport to be complete and are qualified in their entirety by reference to the full text of the Severance Plan and the COC Severance Plan, as adopted on March 23, 2026, copies of which will be filed as exhibits to the Company’s annual report on Form 10-K for the fiscal year ending April 24, 2026.

~~EXHIBIT INDEX~~2

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MiniMed Group, Inc.

Date: March 27, 2026	By:	/s/ Bryan F. Kelly
	Name:	Bryan F. Kelly
	Title:	Senior Counsel, Securities & Corporate Governance, Assistant Corporate Secretary

Filing Compare · MiniMed Group, Inc.